33 results on '"Chia, Stephen"'
Search Results
2. Selective synthesis of triacetyl glyceride biofuel additive via acetylation of glycerol over NiO-supported TiO2 catalyst enhanced by non-microwave instant heating
- Author
-
Appaturi, Jimmy Nelson, R. Jothi Ramalingam, Selvaraj, Manickam, Chia, Stephen, Tan, Soon Huat, Khoerunnisa, Fitri, Ling, Tau Chuan, and Ng, Eng-Poh
- Published
- 2021
- Full Text
- View/download PDF
3. Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.
- Author
-
LeVasseur, Nathalie, Sun, Julia, Fenton, David, Baxter, Simon, Chan, Angela, Roberts, Sarah, Feng, Xiaolan, Lohrisch, Caroline, Gelmon, Karen, Shenkier, Tamara, and Chia, Stephen K
- Published
- 2022
- Full Text
- View/download PDF
4. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
- Author
-
Chan, Arlene, Moy, Beverly, Mansi, Janine, Ejlertsen, Bent, Holmes, Frankie Ann, Chia, Stephen, Iwata, Hiroji, Gnant, Michael, Loibl, Sibylle, Barrios, Carlos H., Somali, Isil, Smichkoska, Snezhana, Martinez, Noelia, Garcia-Alonso, Mirta, Link, John S., Mayer, Ingrid A., Cold, Søren, Morales Murillo, Serafin, Senecal, Francis, and Inoue, Kenichi
- Published
- 2021
- Full Text
- View/download PDF
5. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
- Author
-
LeVasseur, Nathalie, Willemsma, Kaylie-Anne, Li, Huaqi, Gondara, Lovedeep, Yip, Walter C, Illmann, Caroline, Chia, Stephen K, and Simmons, Christine
- Published
- 2019
- Full Text
- View/download PDF
6. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
- Author
-
Hughes-Davies, Luke, Huntsman, David, Ruas, Margarida, Fuks, Francois, Bye, Jacqueline, Chin, Suet-Feung, Milner, Jonathon, Brown, Lindsay A., Hsu, Forrest, Gilks, Blake, Nielsen, Torsten, Schulzer, Michael, Chia, Stephen, Ragaz, Joseph, Cahn, Anthony, Linger, Lori, Ozdag, Hilal, Cattaneo, Elena, Jordanova, E.S., Schuuring, Edward, Yu, David S., Venkitaraman, Ashok, Ponder, Bruce, Doherty, Aidan, Aparicio, Samuel, Bentley, David, Theillet, Charles, Ponting, Chris P., Caldas, Carlos, and Kouzarides, Tony
- Subjects
Breast cancer -- Genetic aspects ,Gene amplification -- Analysis ,Genetic regulation -- Analysis ,Ovarian cancer -- Research ,Biological sciences - Abstract
Research demonstrates that EMSY protein binds BRCA2 within exon 3 region, which is deleted in cancer. It can silence the activation potential of BRCA2 exon 3 and is localized to sites of repair, following DNA damage, on chromosome 11q13.5 involved in breast and ovarian cancer. Furthermore, EMSY gene is amplified in sporadic breast cancer and advanced ovarian cancer.
- Published
- 2003
7. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
- Author
-
Schneeweiss, Andreas, Chia, Stephen, Hickish, Tamas, Harvey, Vernon, Eniu, Alexandru, Waldron-Lynch, Maeve, Eng-Wong, Jennifer, Kirk, Sarah, and Cortés, Javier
- Subjects
- *
ANTHRACYCLINES , *TRASTUZUMAB , *TREATMENT effectiveness , *HEART ventricle diseases , *ANTINEOPLASTIC agents , *BREAST tumors , *COMBINED modality therapy , *CONFIDENCE intervals , *LEFT heart ventricle , *ONCOGENES , *SURVIVAL , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *THERAPEUTICS - Abstract
Background We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. Methods Descriptive efficacy analyses were conducted in patients randomised to group A (cycles 1–6: trastuzumab [8 mg/kg loading dose and 6 mg/kg maintenance] plus pertuzumab [840 mg loading dose and 420 mg maintenance], plus 5-fluorouracil, epirubicin and cyclophosphamide [FEC] [cycles 1–3; 500 mg/m 2 5-fluorouracil/100 mg/m 2 epirubicin/600 mg/m 2 cyclophosphamide] then docetaxel [cycles 4–6; 75 mg/m 2 , escalated to 100 mg/m 2 if well tolerated]), B (cycles 1–3: FEC, cycles 4–6: trastuzumab plus pertuzumab plus docetaxel as mentioned previously) or C (cycles 1–6: trastuzumab plus pertuzumab plus docetaxel [75 mg/m 2 , without dose escalation], and carboplatin [AUC 6]), five years after randomisation of the last patient. This study is registered with ClinicalTrials.gov , number NCT00976989 . Results Three-year Kaplan–Meier survival estimates for disease-free survival (DFS) were 87% (95% confidence interval: 79–95), 88% (80–96) and 90% (82–97) in groups A–C, respectively. Progression-free survival (PFS) rates were 89% (81–96), 89% (81–96) and 87% (80–95). DFS hazard ratio for total pathological complete response (tpCR) versus no tpCR was 0.27 (0.11–0.64). During post-treatment follow-up, 2/72 (2.8%), 3/75 (4.0%) and 4/76 (5.4%) patients in groups A–C had any-grade left ventricular systolic dysfunction; eight (11.1%), 12 (16.0%) and nine (11.8%) patients experienced left ventricular ejection fraction declines ≥10% from baseline to <50%. Conclusions Long-term DFS and PFS were similar between groups. Patients who achieved tpCR had improved DFS. No new safety signals were identified. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
- Author
-
Wilson, Sheridan, Speers, Caroline, Tyldesley, Scott, Chia, Stephen, Kennecke, Hagen, Ellard, Susan, and Lohrisch, Caroline
- Published
- 2016
- Full Text
- View/download PDF
9. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
- Author
-
Addison, Christina L., Pond, Gregory R., Cochrane, Brandy, Zhao, Huijun, Chia, Stephen K., Levine, Mark N., and Clemons, Mark
- Abstract
Background Bone metastases are common in women with breast cancer and often result in skeletal related events (SREs). As the angiogenic factor vascular endothelial growth factor (VEGF) regulates osteoclast activity and is associated with more extensive bone metastases and SRE risk in metastatic breast cancer, we hypothesized that blockade of VEGF signaling could be a therapeutic strategy for inhibiting bone metastases progression and possibly prolonging overall (OS) or progression-free survival (PFS). The Zamboney trial was a randomized placebo-controlled study designed to assess whether patients with bone predominant metastatic breast cancer benefited from addition of the VEGF receptor (VEGFR) targeting agent, vandetanib, to endocrine therapy with fulvestrant. As a companion study, evaluation of biomarkers and their potential association with response to vandetanib or SRE risk was performed. Methods Baseline overnight fasted serum from enrolled patients was analyzed for levels of various putative biomarkers including; VEGF-A, soluble (s)VEGFR2, sVEGFR3, transforming growth factor (TGF)-β1 and activinA by ELISA. Spearman correlation coefficients and Wilcoxon rank sum tests were used to investigate potential relationships between biomarker values and baseline clinical parameters. Prognostic and predictive ability of each marker was investigated using Cox proportional hazards regression with adjustments for treatment and baseline strata of serum CTx (<400 versus ≥400 ng/L). Results Of 129 enrolled patients, serum was available for analysis in 101; 51 in vandetanib and 50 in placebo arm. Mean age amongst consenting patients was 59.8 years. Clinical characteristics were not significantly different between patients with or without serum biomarker data and serum markers were similar for patients by treatment arm. Baseline sVEGFR2 was prognostic for OS (HR=0.77, 95% CI=0.61–0.96, p =0.020), and although a modest association was observed, it was not significant for PFS (HR=0.90, 95% CI=0.80–1.01, p =0.085) nor time to first SRE (HR=0.82, 95% CI=0.66–1.02, p =0.079). When interaction terms were evaluated, sVEGFR2 was not found to be predictive of response to vandetanib, although a modest association remained with respect to PFS (interaction p =0.085). No other marker showed any significant prognostic or predictive ability with any measured outcome. Conclusions In this clinical trial, sVEGFR2 appeared prognostic for OS, hence validation of sVEGFR2 should be conducted. Moreover, the role of sVEGFR2 in breast cancer bone metastasis progression should be elucidated. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. SAPO-34 crystallized using novel pyridinium template as highly active catalyst for synthesis of ethyl levulinate biofuel.
- Author
-
Ma, Yik-Ken, Chia, Stephen, Daou, T. Jean, Khoerunnisa, Fitri, El-Bahy, Salah M., El-Bahy, Zeinhom M., Ling, Tau Chuan, and Ng, Eng-Poh
- Subjects
- *
CATALYST synthesis , *BIOMASS energy - Published
- 2022
- Full Text
- View/download PDF
11. Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials.
- Author
-
Mackey, John R., Kerbel, Robert S., Gelmon, Karen A., McLeod, Deanna M., Chia, Stephen K., Rayson, Daniel, Verma, Sunil, Collins, Loretta L., Paterson, Alexander H.G., Robidoux, André, and Pritchard, Kathleen I.
- Abstract
Abstract: Purpose: Angiogenesis is critical for tumor growth and a promising therapeutic target. This review will summarize and analyze data from clinical trials of anti-angiogenic agents in the treatment of breast cancer (BC). Design: A systematic search of PubMed and conference databases was performed to identify reports of randomized clinical trials investigating specific anti-angiogenic agents in the treatment of BC. Results and discussion: Phase III trials in advanced BC have demonstrated a reduction in the risk of disease progression (22–52%), improved response rates and net improvements in progression-free survival of 1.2 to 5.5months, but no significant improvements in overall survival with the addition of bevacizumab to chemotherapy. Results of phase III trials in early breast cancer have been inconsistent. Bevacizumab-containing regimens have also been associated with higher overall adverse event rates compared to chemotherapy alone. Phase III trials of the tyrosine kinase inhibitor sunitinib were negative, while randomized phase II trials of sorafenib and pazopanib have improved some outcomes when combined with chemotherapy or targeted therapy compared to controls. In addition to expected vascular class safety signals, tyrosine kinase inhibitors show “off-target” side effects. Ongoing clinical trials evaluating combinatorial strategies based on biological synergies and translational studies identifying biological predictors of response will be crucial to establish meaningful clinical benefits in selected BC populations. Conclusion: Most trials of anti-angiogenic agents in BC have reported improved response rate and progression-free survival but no increase in overall survival compared to chemotherapy alone. Optimizing the therapeutic indices of these agents is a focus of ongoing research and will be critical to their future development. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
12. A Phase II Trial of a Neoadjuvant Platinum Regimen for Locally Advanced Breast Cancer: Pathologic Response, Long-Term Follow-up, and Correlation With Biomarkers.
- Author
-
Yerushalmi, Rinat, Hayes, Malcolm M., Gelmon, Karen A., Chia, Stephen, Bajdik, Chris, Norris, Brian, Speers, Caroline, Hassell, Patricia, O'Reilly, Susan E., Allan, Sharon, and Shenkier, Tamara N.
- Published
- 2009
- Full Text
- View/download PDF
13. Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer.
- Author
-
Crabb, Simon J., Cheang, Maggie C. U., Leung, Samuel, Immonen, Taina, Nielsen, Torsten O., Huntsman, David D., Bajdik, Chris D., and Chia, Stephen K.
- Subjects
BREAST cancer ,LYMPH nodes ,PROGNOSIS ,METASTASIS ,LOGISTIC regression analysis ,BIOMARKERS ,SELECTIVE estrogen receptor modulators ,IMMUNOHISTOCHEMISTRY ,EXPERIMENTAL design - Abstract
Background: Axillary lymph node involvement remains the most important prognostic factor in early-stage breast cancer. We hypothesized that molecular classification based on breast cancer biology would predict the presence of nodal involvement at diagnosis, which might aid treatment decisions regarding the axilla. Patients and Methods: From a clinically annotated tissue microarray of 4444 early-stage breast cancers, expression of estrogen receptor (ER), progesterone receptor (PgR), HER2, epidermal growth factor receptor, and cytokeratin 5/6 was determined by immunohistochemistry. Cases were classified by published criteria into molecular subtypes of luminal, luminal/HER2 positive, HER2 positive/ER negative/PgR negative, and basal. Risk of axillary nodal involvement at diagnosis was determined in 2 multivariable logistic regression models: a "core biopsy model" including molecular subtype, age, grade, and tumor size and a "lumpectomy model," which also included lymphovascular invasion. Luminal was used as the reference group. After internal validation of findings in 2 independent sets, we conducted combined analysis of both. Results: In the core biopsy model, the molecular subtypes had a predictive effect for nodal involvement (P = .000001), with the basal subtype having an odds ratio for axillary lymph node involvement of 0.53 (95% CI, 0.41-0.69). Tumor grade (P = 5.43 × 10–12) and size (P = 8.52 × 10–35) were also predictive for nodal involvement. Similar results were found in the lumpectomy model, where lymphovascular invasion was also predictive (P = 2.74 × 10–115). Conclusion: These results indicate that the basal breast cancer molecular subtype predicts a lower incidence of axillary nodal involvement, and including biomarker profiles to predict nodal status at diagnosis could help stratification for decisions regarding axillary surgery and locoregional radiation. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
- Author
-
Chia, Stephen and Gradishar, William
- Subjects
CANCER treatment ,TAMOXIFEN ,CANCER in women ,BREAST cancer ,DISEASES in women - Abstract
Abstract: With the aromatase inhibitors (AIs) replacing tamoxifen as the first-line treatment for postmenopausal women with hormone receptor-positive early and advanced breast cancer, there is a need to evaluate appropriate endocrine treatment options following AI failure. However, until recently, there were no Phase III trial data in this area. Fulvestrant (Faslodex™) is an oestrogen receptor antagonist utilised for the treatment of postmenopausal women with locally advanced or metastatic breast cancer following progression or recurrence on anti-oestrogen therapy. Fulvestrant has a mode of action that is distinct from the AIs and the selective oestrogen receptor modulators, and thus may offer an effective treatment option in the post-AI setting. The Evaluation of Faslodex and Exemestane Clinical Trial (EFECT) is the first Phase III trial to evaluate the efficacy and tolerability of fulvestrant and the steroidal AI, exemestane, in patients with locally advanced or metastatic breast cancer who have progressed or recurred while receiving a non-steroidal AI. EFECT confirmed that fulvestrant and exemestane offer effective treatment options in this setting. Similar efficacy was seen in both treatment groups and there were no significant differences in reported adverse events between fulvestrant and exemestane. The EFECT data provide further evidence for the activity of fulvestrant in the treatment of advanced breast cancer. Other ongoing fulvestrant trials will further define its full role, including the potential for a high-dose regimen, combination of fulvestrant with an AI, and identification of clinical and biological markers to help in targeting those patients who are most likely to respond to treatment. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
15. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.
- Author
-
Dabiri, Shahriar, Huntsman, David, Makretsov, Nikita, Cheang, Maggie, Gilks, Blake, Badjik, Chris, Gelmon, Karen, Chia, Stephen, and Hayes, Malcolm
- Published
- 2004
- Full Text
- View/download PDF
16. PO81 - Ribociclib and Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER-2) Breast Cancer: The Monaleesa Clinical Trials Program.
- Author
-
Campone, Mario, Tripathy, Debu, Chia, Stephen, Diaz-Padilla, Ivan, Lorenc, Karen R., Miller, Michelle, Germa, Caroline, and Conte, Pierfranco
- Subjects
HORMONE therapy ,EPIDERMAL growth factor receptors ,BREAST cancer - Published
- 2017
- Full Text
- View/download PDF
17. When is downstream pathway inhibition important?
- Author
-
Wilson, Sheridan and Chia, Stephen K
- Published
- 2014
- Full Text
- View/download PDF
18. IGF-1R inhibition: right direction, wrong pathway?
- Author
-
Wilson, Sheridan and Chia, Stephen K
- Published
- 2013
- Full Text
- View/download PDF
19. Don't pick the loser: lessons from the GeparQuinto trial
- Author
-
Chia, Stephen K
- Published
- 2012
- Full Text
- View/download PDF
20. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Holmes, Frankie A., Moy, Beverly, Delaloge, Suzette, Chia, Stephen K.L., Ejlertsen, Bent, Mansi, Janine, Iwata, Hiroji, Gnant, Michael, Buyse, Marc, Barrios, Carlos H., Silovski, Tajana, Šeparović, Robert, Bashford, Anna, Zotano, Angel Guerrero, Denduluri, Neelima, Patt, Debra, Gokmen, Erhan, Gore, Ira, Smith II, John W., and Loibl, Sibylle
- Subjects
- *
BREAST cancer prognosis , *ADJUVANT chemotherapy , *CONFIDENCE intervals , *TRASTUZUMAB , *ANTINEOPLASTIC agents , *PROTEIN-tyrosine kinase inhibitors , *TREATMENT effectiveness , *TUMOR classification , *RANDOMIZED controlled trials , *PLACEBOS , *COMPARATIVE studies , *PRE-tests & post-tests , *BLIND experiment , *DESCRIPTIVE statistics , *STATISTICAL sampling , *BREAST tumors , *WOMEN'S health - Abstract
ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved invasive disease-free survival in women with early-stage HER2-positive breast cancer. We report the final analysis of overall survival in ExteNET. In this international, randomised, double-blind, placebo-controlled, phase 3 trial, women aged 18 years or older with stage 1–3c (amended to stage 2–3c) HER2-positive breast cancer who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab were eligible. Patients were randomly assigned to oral neratinib 240 mg/day or placebo for 1 year. Randomisation was stratified according to hormone receptor (HR) status (HR-positive vs. HR-negative), nodal status (0, 1–3 or 4+), and trastuzumab regimen (sequentially vs. concurrently with chemotherapy). Overall survival was analysed by intention to treat. ExteNET is registered (Clinicaltrials.gov: NCT00878709) and is complete. Between July 9, 2009, and October 24, 2011, 2840 women received neratinib (n = 1420) or placebo (n = 1420). After a median follow-up of 8.1 (IQR, 7.0–8.8) years, 127 patients (8.9%) in the neratinib group and 137 patients (9.6%) in the placebo group in the intention-to-treat population had died. Eight-year overall survival rates were 90.1% (95% CI 88.3–91.6) with neratinib and 90.2% (95% CI 88.4–91.7) with placebo (stratified hazard ratio 0.95; 95% CI 0.75–1.21; p = 0.6914). Overall survival in the extended adjuvant setting was comparable for neratinib and placebo after a median follow-up of 8.1 years in women with early-stage HER2-positive breast cancer. • Neratinib improves iDFS after trastuzumab in early HER2+ breast cancer. • We report the final analysis of overall survival from the phase 3 ExteNET trial. • At 8 years' follow-up, OS in the ITT population was similar with neratinib vs placebo. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
- Author
-
Chlebowski, Rowan, Cuzick, Jack, Amakye, Dereck, Bauerfeind, Ingo, Buzdar, Aman, Chia, Stephen, Cutuli, Bruno, Linforth, Rick, Maass, Nicolaì, Noguchi, Shinzaburo, Robidoux, André, Verma, Sunil, and Hadji, Peyman
- Published
- 2009
- Full Text
- View/download PDF
22. Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer.
- Author
-
Sit, Daegan, Lalani, Nafisha, Chan, Elisa, Tran, Eric, Speers, Caroline, Gondara, Lovedeep, Chia, Stephen, Gelmon, Karen, Lohrisch, Caroline, and Nichol, Alan
- Subjects
- *
SENTINEL lymph node biopsy , *CANCER relapse , *AXILLARY lymph node dissection , *EPIDERMAL growth factor receptors , *BREAST cancer , *LYMPH node surgery , *LUMPECTOMY - Abstract
Purpose: Randomized clinical trials have shown that regional nodal irradiation (RNI) in patients with unselected N1 breast cancer improves breast cancer-specific survival. However, the benefit of RNI in women with biologically low-risk N1 breast cancer is uncertain. We conducted a population-based study to determine whether RNI is associated with improved breast cancer recurrence-free interval (BCRFI) in this population.Methods and Materials: Patients aged 40 to 79 years with pT1-2 pN1 (node-positive) breast cancer diagnosed between 2005 and 2014 were identified. The inclusion criteria were modeled off of the TAILOR RT study, which is a randomized noninferiority clinical trial designed to assess the value of RNI in patients with low-risk N1 disease. Eligible patients had breast-conserving surgery or mastectomy and axillary lymph node dissection with 1 to 3 positive nodes, breast-conserving surgery and sentinel lymph node biopsy with 1 to 2 positive nodes, or mastectomy and sentinel lymph node biopsy with 1 positive node. Additionally, patients had luminal A breast cancers, as approximated by estrogen receptor positive (Allred 6-8/8), progesterone receptor (PR) positive (Allred 6-8/8), human epidermal growth factor receptor 2-negative, and grade 1 to 2 immunohistochemical testing. All patients were prescribed hormonal treatment. The primary endpoint of BCRFI, the time to any breast cancer recurrence or breast cancer-related death, was analyzed using a multivariate competing risks analysis.Results: The cohort included 1169 women with a median follow-up of 9.2 years. Radiation treatments were not performed in 151 women treated with mastectomy alone, were delivered to the breast only in 133 women, and were delivered locoregionally in 885 women. Patients undergoing RNI were younger (median age: 58 vs 62 years), more likely to have 2 to 3 macroscopic lymph nodes involved, and more often received chemotherapy (all P < .05). The 10-year estimate of BCRFI was 90% without RNI versus 90% with RNI (P = .5). On multivariable analysis, RNI was not a significant predictor of BCRFI (hazard ratio: 1.0; P = .9).Conclusions: In this retrospective analysis, RNI was not associated with improved BCRFI for women with biologically low-risk N1 breast cancer. We advocate accrual to the ongoing TAILOR RT study. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
23. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
- Author
-
Rugo, Hope S, Lerebours, Florence, Ciruelos, Eva, Drullinsky, Pamela, Ruiz-Borrego, Manuel, Neven, Patrick, Park, Yeon Hee, Prat, Aleix, Bachelot, Thomas, Juric, Dejan, Turner, Nicholas, Sophos, Nickolas, Zarate, Juan Pablo, Arce, Christina, Shen, Yu-Ming, Turner, Stuart, Kanakamedala, Hemanth, Hsu, Wei-Chun, and Chia, Stephen
- Subjects
- *
BREAST cancer , *AROMATASE inhibitors , *HORMONE therapy , *DEATH rate , *KINASE inhibitors , *ERIBULIN , *PROTEINS , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *CELL receptors , *ESTROGEN antagonists , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *TRANSFERASES , *PEPTIDES , *BREAST tumors , *THIAZOLES - Abstract
Background: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A.Methods: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide. Participants aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 2 or less, with no more than two previous anticancer treatments and no more than one previous chemotherapy regimen, were enrolled in three cohorts. In cohort A, patients must have had progression on or after a CDK4/6 inhibitor plus an aromatase inhibitor as the immediate previous treatment. Patients received oral alpelisib 300 mg/day (continuously) plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1. The primary endpoint was the proportion of patients alive without disease progression at 6 months per local assessment using Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with a centrally confirmed PIK3CA mutation. This trial is registered with ClinicalTrials.gov, NCT03056755.Findings: Between Aug 14, 2017, and Dec 17, 2019 (data cutoff), 127 patients with at least 6 months' follow-up were enrolled into cohort A. 121 patients had a centrally confirmed PIK3CA mutation. At data cutoff, median follow-up was 11·7 months (IQR 8·5-15·9). 61 (50·4%; 95% CI 41·2-59·6) of 121 patients were alive without disease progression at 6 months. The most frequent grade 3 or worse adverse events were hyperglycaemia (36 [28%] of 127 patients), rash (12 [9%]), and rash maculopapular (12 [9%]). Serious adverse events occurred in 33 (26%) of 127 patients. No treatment-related deaths were reported.Interpretation: BYLieve showed activity of alpelisib plus fulvestrant with manageable toxicity in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer, after progression on a CDK4/6 inhibitor plus an aromatase inhibitor.Funding: Novartis Pharmaceuticals. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
- Author
-
McCartney, Amelia, Biagioni, Chiara, Schiavon, Gaia, Bergqvist, Mattias, Mattsson, Karin, Migliaccio, Ilenia, Benelli, Matteo, Romagnoli, Dario, Bonechi, Martina, Boccalini, Giulia, Pestrin, Marta, Galardi, Francesca, De Luca, Francesca, Biganzoli, Laura, Piccart, Martine, Gradishar, William J., Chia, Stephen, Di Leo, Angelo, and Malorni, Luca
- Subjects
- *
BREAST cancer prognosis , *EXEMESTANE , *CANCER patients , *CONFIDENCE intervals , *METASTASIS , *RESEARCH funding , *TUMOR markers , *RETROSPECTIVE studies , *DISEASE progression , *PROTEIN kinase inhibitors , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Thymidine kinase 1 (TK1) plays a critical role in DNA synthesis and cell proliferation. Recent studies have shown potential for serum TK1 activity (sTKa) as a prognostic marker and indicator of early response to endocrine therapy in advanced breast cancer. The aim of this study is to assess the correlation between sTKa and patient outcome. The Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) was a double-blind, double-dummy, randomised trial of fulvestrant versus exemestane after progression on non-steroidal aromatase inhibitor therapy, in postmenopausal women with advanced breast cancer. Retrospective analyses of serum archived from EFECT were conducted. sTKa was assessed using the DiviTum® assay on samples collected at baseline, after three and six months of endocrine therapy, and at disease progression. The median time to progression (mTTP) for patients with low baseline sTKa levels was 5.03 months (95% confidence interval [CI]: 3.91–5.89) versus 2.57 months (95% CI: 2.04–3.52) in patients with high sTKa baseline levels (P < 0.0001). On treatment, patients whose sTKa increased from baseline had a significantly shorter mTTP (3.39 months, 95% CI: 2.14–4.11) than those without an sTKa increase (5.39 months, 95% CI: 4.01–6.68) (P = 0.0045). Similar results were observed in the separate EFECT treatment arms. After adjusting for major prognostic factors, sTKa remained an independent marker. sTKa is a potential circulating prognostic marker in patients with advanced breast cancer treated with endocrine therapy. It may also represent a tool for upfront identification of endocrine therapy resistance and early positive response to therapy. Independent validation of these results is warranted. • Retrospective analyses of sera from the Evaluation of Faslodex versus Exemestane Clinical Trial to assess the association between serum thymidine kinase 1 activity (sTKa) and outcome. • Low baseline sTKa correlated with longer median time to progression (mTTP). • Stable or decreased sTKa while on endocrine treatment correlated with longer mTTP. • After adjusting for prognostic factors, sTKa remained an independent marker. • sTKa may identify early endocrine resistance and monitor response in sensitive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Mamounas, Eleftherios P, Bandos, Hanna, Lembersky, Barry C, Jeong, Jong-Hyeon, Geyer, Charles E, Rastogi, Priya, Fehrenbacher, Louis, Graham, Mark L, Chia, Stephen K, Brufsky, Adam M, Walshe, Janice M, Soori, Gamini S, Dakhil, Shaker R, Seay, Thomas E, Wade III, James L, McCarron, Edward C, Paik, Soonmyung, Swain, Sandra M, Wickerham, D Lawrence, and Wolmark, Norman
- Subjects
- *
HORMONE receptor positive breast cancer , *URINARY tract infections , *BREAST cancer , *LETROZOLE , *FEMUR neck , *CANCER relapse , *PROTEIN metabolism , *RESEARCH , *CLINICAL trials , *MULTIVARIATE analysis , *RESEARCH methodology , *CELL receptors , *PROGNOSIS , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *AROMATASE inhibitors , *BLIND experiment , *POSTMENOPAUSE , *RESEARCH funding , *COMBINED modality therapy , *TAMOXIFEN , *BREAST tumors - Abstract
Background: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer.Methods: This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo. Randomisation was stratified by pathological node status, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0·0418. This study is registered with ClinicalTrials.gov, number NCT00382070, is active, and is no longer enrolling patients.Findings: Between Sept 28, 2006, and Jan 6, 2010, 3966 patients were randomly assigned to receive letrozole (n=1983) or placebo (n=1983). Follow-up information was available for 3903 patients for the analyses of disease-free survival. Median follow-up was 6·9 years (IQR 6·1-7·5). Letrozole treatment did not significantly improve disease-free survival (339 disease-free survival events were reported in the placebo group and 292 disease-free survival events were reported in the letrozole group; hazard ratio 0·85, 95% CI 0·73-0·999; p=0·048). 7-year disease-free survival estimate was 81·3% (95% CI 79·3-83·1) in the placebo group and 84·7% (82·9-86·4) in the letrozole group. The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo group vs 50 [3%] of 1941 patients in the letrozole group) and back pain (44 [2%] vs 38 [2%]). The most common grade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common grade 4 adverse events in the letrozole group were urinary tract infection, hypokalaemia, and left ventricular systolic dysfunction (four [<1%] each).Interpretation: After 5 years of aromatase inhibitor-based therapy, 5 years of letrozole therapy did not significantly prolong disease-free survival compared with placebo. Careful assessment of potential risks and benefits is required before recommending extended letrozole therapy to patients with early-stage breast cancer.Funding: National Cancer Institute, Korea Health Technology R&D Project, Novartis. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
26. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
- Author
-
Campone, Mario, Im, Seock-Ah, Iwata, Hiroji, Clemons, Mark, Ito, Yoshinori, Awada, Ahmad, Chia, Stephen, Jagiełło-Gruszfeld, Agnieszka, Pistilli, Barbara, Tseng, Ling-Ming, Hurvitz, Sara, Masuda, Norikazu, Cortés, Javier, De Laurentiis, Michele, Arteaga, Carlos L., Jiang, Zefei, Jonat, Walter, Le Mouhaër, Sylvie, Sankaran, Banu, and Bourdeau, Laurence
- Subjects
- *
BREAST cancer prognosis , *ANTINEOPLASTIC agents , *ASPARTATE aminotransferase , *BREAST tumors , *CELL receptors , *COMBINATION drug therapy , *DNA , *ENZYME inhibitors , *EPIDERMAL growth factor , *HYPERGLYCEMIA , *GENETIC mutation , *TIME , *TUMOR classification , *SELECTIVE estrogen receptor modulators , *STATISTICAL significance , *ALANINE aminotransferase , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *POSTMENOPAUSE , *TUMOR grading , *THERAPEUTICS , *GENETICS - Abstract
Abstract Background Buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus fulvestrant in the BELLE-2 study significantly improved progression-free survival (PFS) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Patients and methods In this phase III study, patients were randomised 1:1 to buparlisib (100 mg/day; continuously in 28-day cycles) or placebo, plus fulvestrant (500 mg on cycle 1 day 15, and day 1 of subsequent cycles). Overall survival (OS) was assessed in the overall population and patients with known PI3K pathway status (both had shown significant PFS improvements). OS by PIK3CA status in circulating tumour DNA (ctDNA) was an exploratory end-point. Results A total of 2025 patients were screened for eligibility between 7th September 2012 and 10th September 2014, and 1178 received fulvestrant (500 mg) during a run-in phase; 31 discontinued. Of 1147 patients (median age 62 years), 98% had the Eastern Cooperative Oncology Group performance status ≤1, and 59% had visceral disease. Median follow-up from randomisation to data cut-off (23rd December 2016) was 37.6 months. Median OS trended in favour of the buparlisib arm in the overall population (33.2 versus 30.4 months; P = 0.045) and among patients with known PI3K pathway status (30.9 versus 28.9 months; P = 0.144); neither outcome was statistically significant. Median OS also trended in favour of buparlisib among patients with PIK3CA -mutant ctDNA (26.0 versus 24.8 months). Grade III/IV adverse events with ≥10% difference between the buparlisib versus placebo arms were elevated alanine aminotransferase (26% versus 1%), elevated aspartate aminotransferase (18% versus 3%) and hyperglycemia (15% versus <1%). Conclusions OS results were in favour of buparlisib plus fulvestrant versus placebo plus fulvestrant; however, there is no statistical significance and more frequent grade III/IV adverse events were reported. Use of more selective PI3K inhibitors might provide the greatest clinical benefit and tolerable safety profile in this setting. Further evaluation of the predictive benefit of PIK3CA -mutant ctDNA is warranted. Trial registration number NCT01610284. Highlights • In this phase III study, median overall survival trended in favour of buparlisib plus fulvestrant versus placebo plus fulvestrant. ○ In the overall population (1147 patients), median OS was 33.2 versus 30.4 months; 1-sided P = 0.045. ○ In patients with known PI3K pathway status (851 patients), median OS was 30.9 versus 28.9 months; 1-sided P = 0.144. • Both outcomes were not statistically significant and more frequent grade III/IV adverse events were reported. • Investigation of selective PI3K inhibitors is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
27. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Martin, Miguel, Holmes, Frankie A, Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Chia, Stephen K L, Mansi, Janine, Barrios, Carlos H, Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Gokmen, Erhan, Bashford, Anna, Ruiz Borrego, Manuel, Kim, Sung-Bae, Jakobsen, Erik Hugger, and Ciceniene, Audrone
- Subjects
- *
TRASTUZUMAB , *BREAST cancer treatment , *ADJUVANT treatment of cancer , *PROTEIN-tyrosine kinase inhibitors , *FOLLOW-up studies (Medicine) , *THERAPEUTICS - Abstract
Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.Methods: In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 years or older (≥20 years in Japan) with stage 1-3c (modified to stage 2-3c in February, 2010) operable breast cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry. Patients who were eligible patients were randomly assigned (1:1) via permuted blocks stratified according to hormone receptor status (hormone receptor-positive vs hormone receptor-negative), nodal status (0 vs 1-3 vs or ≥4 positive nodes), and trastuzumab adjuvant regimen (given sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system, to receive 1 year of oral neratinib 240 mg/day or matching placebo. Treatment was given continuously for 1 year, unless disease recurrence or new breast cancer, intolerable adverse events, or consent withdrawal occurred. Patients, investigators, and trial funder were masked to treatment allocation. The predefined endpoint of the 5-year analysis was invasive disease-free survival, analysed by intention to treat. ExteNET is registered with ClinicalTrials.gov, number NCT00878709, and is closed to new participants.Findings: Between July 9, 2009, and Oct 24, 2011, 2840 eligible women with early HER2-positive breast cancer were recruited from community-based and academic institutions in 40 countries and randomly assigned to receive neratinib (n=1420) or placebo (n=1420). After a median follow-up of 5·2 years (IQR 2·1-5·3), patients in the neratinib group had significantly fewer invasive disease-free survival events than those in the placebo group (116 vs 163 events; stratified hazard ratio 0·73, 95% CI 0·57-0·92, p=0·0083). The 5-year invasive disease-free survival was 90·2% (95% CI 88·3-91·8) in the neratinib group and 87·7% (85·7-89·4) in the placebo group. Without diarrhoea prophylaxis, the most common grade 3-4 adverse events in the neratinib group, compared with the placebo group, were diarrhoea (561 [40%] grade 3 and one [<1%] grade 4 with neratinib vs 23 [2%] grade 3 with placebo), vomiting (grade 3: 47 [3%] vs five [<1%]), and nausea (grade 3: 26 [2%] vs two [<1%]). Treatment-emergent serious adverse events occurred in 103 (7%) women in the neratinib group and 85 (6%) women in the placebo group. No evidence of increased risk of long-term toxicity or long-term adverse consequences of neratinib-associated diarrhoea were identified with neratinib compared with placebo.Interpretation: At the 5-year follow-up, 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity. An analysis of overall survival is planned after 248 events.Funding: Wyeth, Pfizer, and Puma Biotechnology. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Baselga, José, Im, Seock-Ah, Iwata, Hiroji, Cortés, Javier, De Laurentiis, Michele, Jiang, Zefei, Arteaga, Carlos L, Jonat, Walter, Clemons, Mark, Ito, Yoshinori, Awada, Ahmad, Chia, Stephen, Jagiełło-Gruszfeld, Agnieszka, Pistilli, Barbara, Tseng, Ling-Ming, Hurvitz, Sara, Masuda, Norikazu, Takahashi, Masato, Vuylsteke, Peter, and Hachemi, Soulef
- Subjects
- *
HORMONE receptor positive breast cancer , *COMBINATION drug therapy , *POSTMENOPAUSE , *HER2 protein , *CLINICAL drug trials , *PROTEIN analysis , *AMINOPYRIDINES , *ANTINEOPLASTIC agents , *ASPARTATE aminotransferase , *BREAST tumors , *CELL receptors , *CELLULAR signal transduction , *CLINICAL trials , *COMPARATIVE studies , *DNA , *DRUG eruptions , *ESTRADIOL , *EXANTHEMA , *HETEROCYCLIC compounds , *HYPERGLYCEMIA , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *PHOSPHOTRANSFERASES , *PROGNOSIS , *REOPERATION , *RESEARCH , *RESEARCH funding , *SURVIVAL , *EVALUATION research , *ALANINE aminotransferase , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *SEQUENCE analysis - Abstract
Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit.Methods: The BELLE-2 trial was a randomised, double-blind, placebo-controlled, multicentre study. Postmenopausal women aged 18 years or older with histologically confirmed, hormone receptor-positive and human epidermal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer whose disease had progressed on or after aromatase inhibitor treatment and had received up to one previous line of chemotherapy for advanced disease were included. Eligible patients were randomly assigned (1:1) using interactive voice response technology (block size of 6) on day 15 of cycle 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on day 15 of cycle 1, plus intramuscular fulvestrant (500 mg) on days 1 and 15 of cycle 1, and on day 1 of subsequent 28-day cycles. Patients were assigned randomisation numbers with a validated interactive response technology; these numbers were linked to different treatment groups which in turn were linked to treatment numbers. PI3K status in tumour tissue was determined via central laboratory during a 14-day run-in phase. Randomisation was stratified by PI3K pathway activation status (activated vs non-activated vs and unknown) and visceral disease status (present vs absent). Patients, investigators, local radiologists, study team, and anyone involved in the study were masked to the identity of the treatment until unblinding. The primary endpoints were progression-free survival by local investigator assessment per Response Evaluation Criteria In Solid Tumors (version 1.1) in the total population, in patients with known (activated or non-activated) PI3K pathway status, and in PI3K pathway-activated patients. Efficacy analyses were done in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study drug and had at least one post-baseline safety assessment according to the treatment they received. This trial is registered with ClinicalTrials.gov, number NCT01610284, and is currently ongoing but not recruiting participants.Findings: Between Sept 7, 2012, and Sept 10, 2014, 1147 patients from 267 centres in 29 countries were randomly assigned to receive buparlisib (n=576) or placebo plus fulvestrant (n=571). In the total patient population (n=1147), median progression-free survival was 6·9 months (95% CI 6·8-7·8) in the buparlisib group versus 5·0 months (4·0-5·2) in the placebo group (hazard ratio [HR] 0·78 [95% CI 0·67-0·89]; one-sided p=0·00021). In patients with known PI3K status (n=851), median progression-free survival was 6·8 months (95% CI 5·0-7·0) in the buparlisib group vs 4·5 months (3·3-5·0) in the placebo group (HR 0·80 [95% CI 0·68-0·94]; one-sided p=0·0033). In PI3K pathway-activated patients (n=372), median progression-free survival was 6·8 months (95% CI 4·9-7·1) in the buparlisib group versus 4·0 months (3·1-5·2) in the placebo group (HR 0·76 [0·60-0·97], one-sided p=0·014). The most common grade 3-4 adverse events in the buparlisib group versus the placebo group were increased alanine aminotransferase (146 [25%] of 573 patients vs six [1%] of 570), increased aspartate aminotransferase (103 [18%] vs 16 [3%]), hyperglycaemia (88 [15%] vs one [<1%]), and rash (45 [8%] vs none). Serious adverse events were reported in 134 (23%) of 573 patients in the buparlisib group compared with 90 [16%] of 570 patients in the placebo group; the most common serious adverse events (affecting ≥2% of patients) were increased alanine aminotransferase (17 [3%] of 573 vs one [<1%] of 570) and increased aspartate aminotransferase (14 [2%] vs one [<1%]). No treatment-related deaths occurred.Interpretation: The results from this study show that PI3K inhibition combined with endocrine therapy is effective in postmenopausal women with endocrine-resistant, hormone receptor-positive and HER2-negative advanced breast cancer. Use of more selective PI3K inhibitors, such as α-specific PI3K inhibitor, is warranted to further improve safety and benefit in this setting. No further studies are being pursued because of the toxicity associated with this combination.Funding: Novartis Pharmaceuticals Corporation. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
29. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Chan, Arlene, Delaloge, Suzette, Holmes, Frankie A, Moy, Beverly, Iwata, Hiroji, Harvey, Vernon J, Robert, Nicholas J, Silovski, Tajana, Gokmen, Erhan, von Minckwitz, Gunter, Ejlertsen, Bent, Chia, Stephen K L, Mansi, Janine, Barrios, Carlos H, Gnant, Michael, Buyse, Marc, Gore, Ira, IISmith, John, Harker, Graydon, and Masuda, Norikazu
- Subjects
- *
BREAST cancer treatment , *TRASTUZUMAB , *PROTEIN-tyrosine kinase inhibitors , *ADJUVANT treatment of cancer , *HER2 gene , *RANDOMIZED controlled trials , *THERAPEUTICS , *ANTINEOPLASTIC agents , *BREAST tumors , *CANCER invasiveness , *CELL receptors , *COMBINED modality therapy , *COMPARATIVE studies , *DRUG administration , *DOSE-effect relationship in pharmacology , *INTERNATIONAL relations , *LONGITUDINAL method , *MASTECTOMY , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *QUINOLINE , *RESEARCH , *SURVIVAL analysis (Biometry) , *TUMOR classification , *EVALUATION research , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *BLIND experiment , *KAPLAN-Meier estimator - Abstract
Background: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.Methods: We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709.Findings: Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group.Interpretation: Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.Funding: Wyeth, Pfizer, Puma Biotechnology. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
30. 7: Rates of Regional Radiotherapy Receipt Over Time in Low-Risk, Node Positive Breast Cancer.
- Author
-
Sit, Daegan, Lalani, Nafisha, Chan, Elisa, Tran, Eric, Speers, Caroline, Gondara, Lovedeep, Chia, Stephen, Gelmon, Karen, Lohrisch, Caroline, and Nichol, Alan
- Subjects
- *
BREAST cancer , *RADIOTHERAPY - Published
- 2022
- Full Text
- View/download PDF
31. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study
- Author
-
Shaffer, Richard, Tyldesley, Scott, Rolles, Martin, Chia, Stephen, and Mohamed, Islam
- Subjects
- *
ACUTE toxicity testing , *TRASTUZUMAB , *CANCER radiotherapy , *CARDIOMYOPATHIES , *BREAST cancer patients , *CANCER chemotherapy - Abstract
Abstract: Purpose: To examine the acute cardiotoxicity of internal mammary chain (IMC) irradiation with concurrent trastuzumab. Materials and Methods: Clinical and cardiac function data were collected on 59 patients with early breast cancer who were treated with adjuvant trastuzumab and chemotherapy with or without radiotherapy (often including IMC) at BC Cancer Agency in 2005. Results: Forty-four of fifty-nine patients received adjuvant radiotherapy (RT). Thirteen had left-sided IMC RT. For left-sided RT, IMC inclusion increased the mean percentage dose to 5% of the heart, but the mean doses to 50% and 90% of the heart were similar. Median baseline left ventricular ejection fraction (LVEF) was 62% and similar in all groups. Median absolute decrease in LVEF after RT was 4%, which was not significantly different according to side or inclusion of IMCs. Trastuzumab was stopped in 11 of 59 patients (18.6%) due to decrease in LVEF. After median follow up of 15 months, three patients developed clinical congestive heart failure, none of whom received left-sided IMC RT. Conclusions: There was no excess acute cardiotoxicity observed with the combination of left-sided IMC irradiation and concurrent trastuzumab. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
32. Ultrasmall Cs-AlMCM-41 basic catalysts: Effects of aluminum addition on their physico-chemical and catalytic properties.
- Author
-
Ng, Eng-Poh, Abdullahi, Haruna, Wong, Ka-Lun, Ginés-Molina, María José, Maireles-Torres, Pedro, Rigolet, Severinne, Daou, T. Jean, Chia, Stephen, and Lee, Hooi Ling
- Subjects
- *
ALUMINUM catalysts , *ALDOL condensation , *SILICA gel , *CONDENSATION reactions , *ACETIC anhydride , *BENZALDEHYDE - Abstract
In this study, ultra-small MCM-41 mesoporous solids (<30 nm) were synthesized using colloidal silica and cesium hydroxide as cheap silica source and mineralizer, respectively. Four samples with a SiO 2 /Al 2 O 3 ratio of 5, 20, 30 and ∞ (designated as CsM-5, CsM-20, CsM-30 and CsM-∞, respectively) have been prepared. The effects of SiO 2 /Al 2 O 3 ratio on the formation, physico-chemical and catalytic properties of CsMCM-41 nanoparticles were studied. The results show that incorporation of high content of Al atoms into the framework reduces the ordering of the mesostructure, and hence the porosity of the solids decreases. By using CsOH as mineralizer, the morphology and the size of CsMCM-41 were also tuned from 3-D nanospheres (CsM-5: 29 nm and CsM-20: 27 nm) to hollow nanospheres with very thin walls (CsM-30: 25 nm, CsM-∞: 20 nm) when Al content was decreased. The basicity of CsMCM-41 nanoparticles was also affected by the Al and Cs contents. Hence, their catalytic behavior in the base-catalyzed reactions such as aldol condensation of heptanal with benzaldehyde, and Perkin condensation of benzaldehyde with acetic anhydride was evaluated under microwave heating conditions. CsM-20 displays the best catalytic activities among the samples studied, achieving 87.2% conversion and 78.4% selectivity to jasminaldehyde under optimum reaction conditions, while it also shows comparable catalytic performance as NaOH homogeneous catalyst in the Perkin condensation reaction under non-microwave instant heating conditions. Image 1 • One-pot synthesis of ultra-small AlMCM-41 nanoparticles (<30 nm) is reported. • Colloidal silica and cesium hydroxide are used as cheap silica source and mineralizer. • The effects of Al incorporation on MCM-41 nanoparticles are studied. • The changes in morphological and porosity properties of nanosolids are observed. • The nanoparticles exhibit good catalytic performance in aldol condensation reaction. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. In response to Dr Belkacemi et al.
- Author
-
Tyldesley, Scott, Shaffer, Richard, Mohamed, Islam, Chia, Stephen, and Rolles, Martin
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.